Myeloid leukemia after cytotoxic therapy and other hematotoxins.
Larson
R A
RA
Department of Medicine, Pritzker School of Medicine and Cancer Research Center, University of Chicago, Illinois 60637, USA. rlarson@medicine.bsd.uchicago.edu
D000208:Acute Disease; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007951:Leukemia, Myeloid / Q000139:chemically induced / Q000209:etiology* / Q000235:genetics; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000209:etiology* / Q000235:genetics; D011878:Radiotherapy / Q000009:adverse effects; D059005:Topoisomerase II Inhibitors
D018906:Antineoplastic Agents, Alkylating; D004791:Enzyme Inhibitors; D059005:Topoisomerase II Inhibitors